SUPN:NSD-Supernus Pharmaceuticals Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 37.83

Change

+1.22 (+3.33)%

Market Cap

USD 1.05B

Volume

0.43M

Analyst Target

USD 29.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
ITCI Intracellular Th

-0.27 (-0.31%)

USD 9.17B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing SUPN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.72% 82% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.72% 80% B- 80% B-
Trailing 12 Months  
Capital Gain 34.91% 70% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.91% 70% C- 73% C
Trailing 5 Years  
Capital Gain 73.29% 83% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.29% 83% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 10.68% 54% F 63% D
Dividend Return 10.68% 54% F 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.26% 89% A- 72% C
Risk Adjusted Return 45.93% 89% A- 75% C
Market Capitalization 1.05B 88% B+ 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.30 10% 4%
Price/Book Ratio 2.01 57% 48%
Price / Cash Flow Ratio 17.33 15% 18%
Price/Free Cash Flow Ratio 13.22 24% 28%
Management Effectiveness  
Return on Equity 0.56% 78% 60%
Return on Invested Capital 1.08% 70% 60%
Return on Assets 1.95% 77% 73%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector